Nearly $2M in Starling Oncology (STLN) stock planned for director sale

Rhea-AI Filing Summary

Starling Oncology, Inc. (STLN) received a notice that director Bradford Hively plans a Rule 144 sale of up to 298,853 shares of common stock through Morgan Stanley Smith Barney LLC. The shares have an indicated aggregate market value of $1,954,498.62, with 101,916,115 shares outstanding and an approximate sale date of August 21, 2026. The filing lists prior acquisition methods including open market purchases and restricted stock units.

Key Figures

Shares to be sold: 298,853 shares Aggregate market value: $1,954,498.62 Shares outstanding: 101,916,115 shares +3 more

6 metrics

Shares to be sold 298,853 shares Number of Starling Oncology, Inc. common shares covered by the Form 144 notice

Aggregate market value $1,954,498.62 Aggregate market value of the 298,853 shares proposed to be sold

Shares outstanding 101,916,115 shares Number of Starling Oncology, Inc. common shares outstanding referenced in the notice

Approximate date of sale 08/21/2026 Approximate sale date specified for the Rule 144 transaction

Acquisition date (open market purchase) 11/26/2024 One of the acquisition dates for shares referenced in the filing

Acquisition date (restricted stock units) 11/21/2025 Acquisition date for shares obtained via restricted stock units

Key Terms

Rule 144, restricted stock units, Open Market Purchase, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

restricted stock units financial

"Common | 11/21/2025 | Restricted Stock Units | Issuer"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Open Market Purchase financial

"Common | 11/26/2024 | Open Market Purchase | Issuer"

An open market purchase is when a company buys its own shares on public stock exchanges the same way any investor would, rather than through a private deal. Investors care because these purchases reduce the number of shares available, can boost earnings per share and share price, signal that management thinks the stock is undervalued, and use company cash that might otherwise go to reinvestment or dividends — like a business quietly buying back its own tickets at the box office.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services ... | 1954498.62"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

What insider transaction is disclosed for STLN in this Form 144?

Director Bradford Hively filed a notice to sell up to 298,853 shares of Starling Oncology, Inc. common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an approximate sale date of August 21, 2026.

How many Starling Oncology (STLN) shares are proposed to be sold and on what exchange?

The notice covers up to 298,853 shares of Starling Oncology, Inc. common stock, proposed to be sold on the NASDAQ market.

What is the aggregate market value of the STLN shares covered by this Form 144?

The Form 144 lists an aggregate market value of $1,954,498.62 for the 298,853 Starling Oncology, Inc. shares proposed to be sold.

How many Starling Oncology (STLN) shares are outstanding as referenced in the filing?

The filing states that 101,916,115 shares of Starling Oncology, Inc. common stock were outstanding, providing context for the size of the 298,853-share proposed sale.

What types of acquisitions are referenced for the STLN shares in this Form 144?

The shares referenced in the Form 144 were acquired through open market purchases dated November 26, 2024 and December 2, 2024, and through restricted stock units dated November 21, 2025.

Who is the broker handling the proposed STLN share sale?

The proposed sale of Starling Oncology, Inc. shares will be handled by Morgan Stanley Smith Barney LLC, Executive Financial Services, as listed in the Form 144 securities information section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 04:36 PM Accepted by SEC EDGAR 08/21/2026 - 04:35 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001891124
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Starling Oncology, Inc.
SEC File Number	001-39248
Address of Issuer	18000 Studebaker Road, Suite 800 Cerritos CALIFORNIA 90703
Phone	562-735-3226
Name of Person for Whose Account the Securities are To Be Sold	BRADFORD HIVELY
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	298853	1954498.62	101916115	08/21/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/26/2024	Open Market Purchase	Issuer			229779	11/26/2024	Cash
Common	12/02/2024	Open Market Purchase	Issuer			50000	12/02/2024	Cash
Common	11/21/2025	Restricted Stock Units	Issuer			19074	11/21/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/21/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/22/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Bradford Hively
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)